Patents by Inventor Kenneth W. Duncan

Kenneth W. Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20250145597
    Abstract: Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: October 23, 2024
    Publication date: May 8, 2025
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Young-tae Lee, Jennifer Castro, Scott Ribich, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills, Gavin Whitlock, Andrew J. Jennings
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12233065
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: February 25, 2025
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 12168015
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 17, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Aryl-OR heteroaryl-substituted benzene compounds
    Patent number: 12168016
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 17, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 12161645
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: December 10, 2024
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Inhibitors of RNA helicase DHX9 and uses thereof
    Patent number: 12162867
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: December 10, 2024
    Assignee: ACCENT THERAPEUTICS, INC.
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240316047
    Abstract: Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 26, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF
    Publication number: 20240279210
    Abstract: Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: August 22, 2024
    Inventors: Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling, Andrew Stewart Tasker, Gavin Whitlock
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20240277723
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 22, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Suji SHIROTORI, Satoshi KAWANO
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20240245698
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 25, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20240245697
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 15, 2024
    Publication date: July 25, 2024
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J.N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • METTL3 MODULATORS
    Publication number: 20230027361
    Abstract: Provided are compounds of Formula (I?) or (II?), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 20, 2020
    Publication date: January 26, 2023
    Applicant: Accent Therapeutics, Inc.
    Inventors: Thomas Andrew Wynn, Brian Lewis Hodous, Paula Ann Boriack-Sjodin, Ernest Allen Sickmier, James Edward John Mills, Robert A. Copeland, Andrew Stewart Tasker, Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling
  • QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20220144812
    Abstract: The present disclosure provides novel compounds, compositions comprising the compounds and methods of use thereof.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Epizyme, Inc.
    Inventors: Eamon Comer, Kenneth W. Duncan, Alexis Cocozaki, John Campbell, Darren Harvey, Michael Munchhof
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20210379076
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 9, 2021
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20210308121
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    Type: Application
    Filed: March 2, 2021
    Publication date: October 7, 2021
    Applicant: Epizyme, Inc.
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 11052093
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 6, 2021
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • PRMT5 inhibitors and uses thereof
    Patent number: 10980794
    Abstract: Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: April 20, 2021
    Assignee: Epizyme, Inc.
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin
  • SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20200317643
    Abstract: The present invention relates to substituted 6,5-fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 8, 2020
    Inventors: Kevin W. KUNTZ, Edward J. OLHAVA, Richard CHESWORTH, Kenneth W. DUNCAN
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20200155562
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • PRMT5 inhibitors and uses thereof
    Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash